|
๐
|
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
12 auth.
A. Kavanaugh,
I. McInnes,
P. Mease,
G. Krueger,
D. Gladman,
J. Gรณmez-Reino,
...
K. Papp,
J. Zrubek,
S. Mudivarthy,
M. Mack,
S. Visvanathan,
A. Beutler
|
9 |
2009 |
9
๐
|
|
๐
|
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
13 auth.
R. Inman,
John C. Davis,
D. Heijde,
L. Diekman,
J. Sieper,
Sung Il Kim,
M. Mack,
John Han,
S. Visvanathan,
Zhenhua Xu,
...
B. Hsu,
A. Beutler,
J. Braun
|
9 |
2008 |
9
๐
|
|
๐
|
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor ฮฑ inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
13 auth.
J. Smolen,
J. Kay,
M. Doyle,
R. Landewรฉ,
E. Matteson,
J. Wollenhaupt,
N. Gaylis,
F. Murphy,
J. Neal,
Yiying Zhou,
...
S. Visvanathan,
E. Hsia,
Mahboob Rahman
|
9 |
2009 |
9
๐
|
|
๐
|
Golimumab, a human antibody to tumour necrosis factor ฮฑ given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
14 auth.
E. Keystone,
M. Genovese,
Lars Klareskog,
E. Hsia,
S. Hall,
P. Miranda,
J. Pazdur,
S. Bae,
William E. Palmer,
J. Zrubek,
...
M. Wiekowski,
S. Visvanathan,
Zhong Wu,
Mahboob Rahman
|
8 |
2008 |
8
๐
|
|
๐
|
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab bef
15 auth.
P. Emery,
R. Fleischmann,
L. Moreland,
E. Hsia,
I. Strusberg,
P. Durez,
P. Nash,
E. Amante,
M. Churchill,
W. Park,
...
B. Pons-Estel,
M. Doyle,
S. Visvanathan,
Weichun Xu,
Mahboob Rahman
|
8 |
2009 |
8
๐
|
|
๐
|
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
39 auth.
N. Ruperto,
D. Lovell,
R. Cuttica,
N. Wilkinson,
P. Woo,
G. Espada,
C. Wouters,
E. Silverman,
Z. Balogh,
M. Henrickson,
M. Apaz,
E. Baildam,
A. Fasth,
V. Gerloni,
P. Lahdenne,
...
A. Prieur,
A. Ravelli,
R. Saurenmann,
M. Gamir,
N. Wulffraat,
L. Marรณdi,
R. Petty,
R. Joos,
F. Zulian,
D. McCurdy,
B. Myones,
K. Nagy,
P. Reuman,
I. Szer,
S. Travers,
A. Beutler,
G. Keenan,
Jason Clark,
S. Visvanathan,
A. Fasanmade,
A. Raychaudhuri,
A. Mendelsohn,
A. Martini,
E. Giannini
|
8 |
2007 |
8
๐
|
|
๐
|
Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis
10 auth.
G. Hoffman,
M. Cid,
Karen E Rendt-Zagar,
P. Merkel,
C. Weyand,
J. Stone,
...
C. Salvarani,
Weichun Xu,
S. Visvanathan,
Mahboob Rahman
|
8 |
2007 |
8
๐
|
|
๐
|
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
22 auth.
B. Feagan,
W. Sandborn,
G. D'Haens,
J. Panรฉs,
A. Kaser,
M. Ferrante,
E. Louis,
D. Franchimont,
O. Dewit,
U. Seidler,
...
Kyung-Jo Kim,
M. Neurath,
S. Schreiber,
Paul Scholl,
Chandrasena R Pamulapati,
Bojan Lalovic,
S. Visvanathan,
S. Padula,
I. Herichova,
A. Soaita,
D. Hall,
W. Bรถcher
|
8 |
2017 |
8
๐
|
|
๐
|
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
16 auth.
D. Baeten,
M. รstergaard,
J. Wei,
J. Sieper,
P. Jรคrvinen,
L. Tam,
C. Salvarani,
Tae-Hwan Kim,
A. Solinger,
Y. Datsenko,
...
Chandrasena R Pamulapati,
S. Visvanathan,
D. Hall,
S. Aslanyan,
P. Scholl,
S. Padula
|
8 |
2018 |
8
๐
|
|
๐
|
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
12 auth.
J. Kay,
E. Matteson,
B. Dasgupta,
P. Nash,
P. Durez,
S. Hall,
...
E. Hsia,
John Han,
C. Wagner,
Zhenhua Xu,
S. Visvanathan,
Mahboob Rahman
|
8 |
2008 |
8
๐
|
|
๐
|
Risankizumab versus Ustekinumab for ModerateโtoโSevere Plaque Psoriasis
17 auth.
K. Papp,
A. Blauvelt,
M. Bukhalo,
M. Gooderham,
J. Krueger,
J. Lacour,
A. Menter,
S. Philipp,
H. Sofen,
S. Tyring,
...
B. Berner,
S. Visvanathan,
Chandrasena R Pamulapati,
Nathan L. Bennett,
M. Flack,
P. Scholl,
S. Padula
|
8 |
2017 |
8
๐
|
|
๐
|
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
13 auth.
J. Krueger,
L. Ferris,
A. Menter,
F. Wagner,
A. White,
S. Visvanathan,
Bojan Lalovic,
S. Aslanyan,
E. Wang,
D. Hall,
...
A. Solinger,
S. Padula,
P. Scholl
|
7 |
2015 |
7
๐
|
